AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

DRUG SYNTHESIS USING SUZUKI RXN..Imidazolium ionic liquid-tagged palladium complex: an efficient catalyst for the Heck and Suzuki reactions in aqueous media

 polymorph  Comments Off on DRUG SYNTHESIS USING SUZUKI RXN..Imidazolium ionic liquid-tagged palladium complex: an efficient catalyst for the Heck and Suzuki reactions in aqueous media
Jul 172014
 

Green Chem., 2014, Advance Article
DOI: 10.1039/C4GC00525B, Paper
*
Corresponding authors
a
Department of Chemistry, Birla Institute of Technology and Science, Pilani, Pilani Campus, India
E-mail: bkhungar@pilani.bits-pilani.ac.in,anilkumar@pilani.bits-pilani.ac.in;
Fax: +91 5196 244183 ;
Tel: +91 5196 5155652

A highly recyclable ionic liquid-tagged palladium complex has been synthesized and used as an efficient catalyst for Suzuki and Heck couplings in aqueous media.

An air stable, water soluble, and efficient ionic liquid-tagged Schiff base palladium complex was prepared. The synthesized complex was well characterized by NMR, mass spectrometry, FT-IR, UV-visible spectroscopy and powder X-ray diffraction. The complex was used as a catalyst for the Suzuki and Heck cross-coupling reactions in water. Good to excellent yields were achieved using a modest amount of the catalyst. In addition, the catalyst can be easily reused and recycled for six steps without much loss in activity, exhibiting an example of sustainable and green methodology.

 

Share

Structural and physicochemical aspects of hydrochlorothiazide co-crystals

 Uncategorized  Comments Off on Structural and physicochemical aspects of hydrochlorothiazide co-crystals
Jul 172014
 

Structural and physicochemical aspects of hydrochlorothiazide co-crystals

CrystEngComm, 2014, 16,6996-7003
DOI: 10.1039/C4CE00666F, Paper
*

Corresponding authors

aPharmaceutical Analytical & Solid-State Chemistry Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

The drug-drug co-crystal of hydrochlorothiazide with pyrazinamide is a potential candidate for development of hydrochlorothiazide formulations for combinational therapy.

Crystal engineering principles were employed in designing new co-crystals of hydrochlorothiazide (HCT). A variety of potential co-crystal formers were initially identified in a search of the Cambridge Structural Database with complementary hydrogen-bonding functionalities. Subsequent co-crystallization screening monitored by powder X-ray diffraction led to the discovery of new crystalline phases of HCT with pyrazinamide (1), 4,4′-bipyridine (2), 1,2-bis(4-pyridyl)ethane (3), and trans-1,2-bis(4-pyridyl)ethylene (4). All of the resulting co-crystals were thoroughly characterized by X-ray diffraction, FT-IR and Raman spectroscopy, and thermal analysis. Noticeably, the co-crystal 1 involves the formation of drug–drug co-crystals of HCT and pyrazinamide, which makes it a potential candidate for development of HCT formulations for combinational therapy.
Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: